Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
From Advanced Cell Technology group on FB
This is from the recent article and this is Robert Lanza speaking.
This was posted because it directly refutes part of the recent SA article.
“We went in with our iPS and embryonic stem cells and now they can see again, which is amazing,” he continues. He’s talking even faster than usual and chuckles after he says, “We always thought this blindness was irreversible, but …
“We’re able to put in new photoreceptors and actually reverse the blindness after they’re already blind,” he adds. “That’s huge. No one’s ever done that. If you’d asked me a few years ago whether that was even biologically possible, I would have said probably not.”
It wasn't that long ago there was a 10 for 1 reverse split and really I'd have to have the pps hit somewhere around $17 to break even....something is hinky .... I bought around the time an executive from the company bought...pre split up near $3 dollars...thinking like many investors that this was a good sign...perhaps it was something else ....
Yeh, approved share is different than Outstanding shares....could be leverage as they seek renewed funding from BP
This is just about as good as news as we can expect from Tengion.
"A lot is happening, but can't say anything concrete about it" for legal reasons no doubt.
This stock PPS reminds me of a song, "there's a hole in the bucket....
There will be a leaping!
Yes, when the data is published....something else will no doubt happen as well...probably something pretty big, and the valuation at pps will also reflect that....a number of things are cooking...IMO
Interesting work from one of Dr Lanza's professor colleagues at Wake Forrest:http://www.wakehealth.edu/News-Releases/2014/Laboratory-Grown_Vaginas_Implanted_in_Patients%2C_Scientists_Report.htm
Matt Vincent has stated that the March Invivo article that has gotten much attention, but was never officially published, not be promoted. On the record he denies he ever made any mention of a trial participant by name. As usual, the journalist has overstepped their bounds of journalist responsibility...So there is no official connection between ACTC and Billy W. as mentioned...
Disregard the Invivo article....even though much of it may be true, it was just sloppy journalism is suppose....still the TLD shall come out and when it does, it will probably be officially amazing!!
"Great 50 percent, me being curious wonders why not the other 50 percent. when they figure that out then watchout.."
The gains in visual acuity have something to do with having viable photoreceptors....also they have now created photoreceptors, so this is well on the way to being figured out!
A company with good mojo benefits all with RS...if the mojo is bad....then the RS will not be pretty....ACTC has good mojo
Nice post, farviewhill
Not quite sure what you prefer...uplist to nasdaq via R/S is great progress, yes? It seems like the only path as it will increase shareholder total value as large institutional investors will then take a position....of course it all hinges on continued trial success...best to get up there on that Nasdaq to deepen and widen that investor pool...more fun for every one.
The returns will be huge, but imagine the pleasure when down the road you happen to meet someone who tells you their story about how their sight was returned...and you know you were part of making that possible.
IMO, the PPS drop was due to millions and millons of shares sold by recent litigated shares disbursed. Likely it has been going on since the first day of settlement possible, June 4th. Plus some shares sold by the daily trader folks who know they can buy them back at a lower price. Perhaps the sellers took a breather today....maybe the glut of sales is over. If there are more shares than hit the market than there are buyers, naturally the M.M. will lower the price and buy what retail won't.
Please stop calling this company a turd, that is name calling, these posts should be deleted....where are the people who take care of the board?
Monday Monday....don't like that day.
The Settlement places no restrictions on the shares, just that they be delivered within 5 business days of the 4th. That is why I say, ACTC probably just did it on the 4th to get it over with, the purpose of settling was to get it over with and move on. The restrictions in the settlement address what kind of moves AG might make with that number of shares. The year long prohibition is on any kind of business influence they might try to undertake alone or in collusion with any possible partners.
Regarding the AG settlement shares. The decision was that the shares that were settled for could be delivered starting June 4th, the day of the settlement. IMO, ACTC did just that, delivered all the shares that day, after all, why wait? Since we have no way of knowing, lets assume that the share volume increase is due to the sales of such share (why not). Taking 6 million as an average amount of shares traded, I'm being conservative and the number may be quite a bit higher, I estimate that 145 million of those shares have hit the market so far. There has been about 187 million shares traded since June 4th.
"With a 20% gap in the share price requirement to uplist (requirement is $4 per share after the split). Do you think we get the news of the reverse split before or after the publication of interim data? Just trying to figure out what comes next. My guess is they like to see the share price stable a bit before announcing the next event either way. In my mind it may be better to announce the split next and hope news is around the corner. All the negatives would be off the table."
It seems like there are advantages to news before (sp would go up, and the ratio would be smaller), but I would think more investor value will be added if the TLD is timed to occur right after the RS and uplist as then what really increases the market cap will be the institutional investors as then our little stock will be eligible regarding their policy (sp level and exchange). I've been led to believe there are numerous investment groups who are awaiting these changes in status.
That statement that something is good for the company and bad for the investor defies logic. If it is good for the company, and we are part owners of the company as shareholders, it will be good for us as well.
It is always presumptuous to think a RS with uplist will hurt PPS. I suppose if you say it often enough, some will act on it and make it seem so....Let us repeat again and again how some stocks desperately try to stay on the higher exchange with reverse splits, now that is a danger sign, but a stock on reverse split to access larger investment pool, that leads to value growth, PPS wise....lets wise up and uplist!
Attention, special sale - temporary price reduction on SP for ACTC No limit for purchases. Enjoy!
Note:Not meant as a reply to Killtoys message, just a general message.
I would think so, I suspect the shares that went to legal council are part of what we are seeing. Just a guess, but I think Aronson will not sell too much since he has some idea of what ACT has got coming up.
Delivered within 5 business days of June 4th.
Yesterday, or anytime after June 4th.
http://ir.advancedcell.com/all-sec-filings/content/0001019687-14-002326/advancedcell_8k.htm
I was singing this song today as well!
Negatives in the rear view mirror...awesome!
"Dr. Lanza also previously served as a Clinical
Associate Professor of Surgery at Tufts University and as an Associate in
Surgery at Harvard Medical School and New England Deaconess Hospital's
Division of Organ Transplantation."
http://www.prnewswire.com/news-releases/advanced-cell-technology-appoints-robert-lanza-md-to-lead-tissue-engineering-and-transplant-research-75507752.html
This is from an old article, but it is interesting to see the connection to Tufts.
Meanwhile humans around the globe are creating, without FDA approval, embryos everyday. Here's to hoping ACT can make this a better world for them.
So the company indicates that the shares were issued,
"Camofi/Camhzn Debt
From the period January 1, 2014 through March 17, 2014, the Company received conversion notices for a total of approximately $2,400,000. The Company issued 43,373,609 shares of its common stock for these conversion notices. As a result the outstanding amount of the Camofi Senior Secured Convertible Debentures has been reduced to approximately $1,200,000. "
From 10-k (the SEC is in on this as well)
I don't know which document you prefer, the 8-k or the 10-k.
"Default" ????
From PAL of Icell:
"This information was also in the 10-K p.F-41,
From the period January 1, 2014 through March 17, 2014, the Company received conversion notices for a total of approximately $2,400,000. The Company issued 43,373,609 shares of its common stock for these conversion notices. As a result the outstanding amount of the Camofi Senior Secured Convertible Debentures has been reduced to approximately $1,200,000.
This indicates that CAM has already converted, and been issued, the equivalent of all of this year's scheduled quarterly payments, leaving only 03/31/15 and 06/30/15 payments remaining...$1.2M.
Bottom line, and for final clarification for anyone how reads this...ACT did not miss a payment, and they have issued, according to this recent 10-K all shares associated with the 6 conversion notices they have received from CAM since settlement."